Last week Medical Marijuana, Inc. (OTC Pink: MJNA) announced that its flagship product Real Scientific Hemp Oil™ (RSHO™) has again made world history as the first cannabis product to be approved on a case-by-case basis for Parkinson’s disease by the Brazilian Government Health Agency ANVISA, which is responsible for approving citizen importation of medicines not found in Brazil.
Following Epilepsy (CDKL5 and Dravet Syndrome), which was the first indication to be approved, Parkinson’s Disease becomes the second approved indication of Medical Marijuana, Inc.’s RSHO by Brazil’s ANVISA for importation with medical recommendation. Medical Marijuana, Inc. and its partner company HempMeds Brasil are working diligently within the framework of the Brazilian Government for approvals of at least five other indications.
Brazil Approves RSHO For Parkinson’s Treatment
MJNA’s partner HempMeds Brasil is providing the RSHO exclusively for the Brazilian marketplace while under temporary case-by-case approval for several additional medical indications, subject to clinical trials within the country.
Today, any resident of Brazil who has a government-approved medical indication and who would like to have access to RSHO hemp oil products, may do so with a doctor’s prognosis, prescription and government-approved import documentation. ANVISA has issued a statement on the agency’s website and has also made an effort to explain how to apply for an import certificate. HempMeds Brasil has been working for over a year on its formal product application and regulatory submission. The company expects this process to be completed by the end of 2015.
Brazilian Orlando Mesquita is battling Parkinson’s and has been taking RSHO for the past four weeks. Mesquita says he is, “sleeping better and my movements are much more fluid and controlled.” In that short period of time, Mesquita’s wife has already noticed a 50% improvement with her husband’s medical condition.
The government of Brazil, with their 1988 Constitutional right of free health care (SUS) to all citizens, is again leading the way by putting the well-being of their people first. RSHO products have been provisionally approved and are being reviewed for potentially six other medical indications, which are subject to future clinical trials. – Stuart W. Titus, PhD – CEO of Medical Marijuana, Inc.
In 2005, the number of Parkinson’s patients worldwide was between 4.1 and 4.6 million. By the year 2030, those numbers are expected to more than double to 8.7 and 9.3 million patients according to the European Parkinson’s Disease Association. The Parkinson’s Disease foundation states that, in the U.S. alone, Parkinson’s is estimated to cost nearly $25 billion every year in combined direct and indirect costs.
Hemp is widely regarded as a superfood and MJNA’s cannabidiol (CBD) hemp oil is derived from the mature stalk of the hemp plant and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic/euphoric effects of THC. Although CBD hemp oil products are readily available in America, hemp oil products are handled quite differently in Brazil.
Until recently, the Brazilian government treated anything derived from cannabis, including hemp, as an illegal controlled substance. However, in a series of landmark rulings, the Brazilian government began permitting the importation of hemp CBD oil products with registration by the Federal government agency ANVISA. The Federal government agency also removed CBD from its prohibited substance use list.
What do you think about Brazil’s decision to allow medical hemp treatments for Parkinson’s disease? Join the conversation and comment below!
